The reiteration of a Buy rating and maintenance of a $12 price target by HC Wainwright & Co. analyst Raghuram Selvaraju is a positive signal for Cocrystal Pharma. This indicates that the analyst continues to have confidence in the company's prospects, which could lead to increased investor interest and a potential short-term increase in the stock price.